文献速递病毒性肝炎

住院注射吸毒者丙型肝炎感染的机会性治疗(OPPORTUNI-C):阶梯楔形整群随机试验

Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在挪威奥斯陆三家医院的内科、成瘾医学科和精神科病房开展阶梯楔形整群随机试验,纳入200例HCV RNA阳性住院者。干预组治疗完成率68.4%,对照组35.3%(风险差33.1%,风险比1.9),干预在治疗完成(aOR 4.8,P=.002)和启动治疗时间(aHR 4.0,P<.001)上均更优。作者认为机会性检测-治疗模式应被考虑更广泛实施。

要点

  • 住院注射吸毒者中,机会性立即启动HCV治疗较标准转诊门诊的完成率更高。
  • 干预组治疗完成率68.4%,对照组35.3%,风险比1.9(95%CI 1.4-2.6)。
  • 持续病毒学应答干预组61.2%,对照组64.7%。

核心结论

  • 在住院注射吸毒者中,丙型肝炎病毒机会性检测-治疗模式优于标准诊疗。
  • 作者认为该照护模式应考虑更广泛实施。

研究设计与样本

  • 务实性阶梯楔形整群随机试验,在挪威奥斯陆三家医院的内科、成瘾医学科和精神科病房招募HCV RNA阳性住院者。
  • 七个科室按顺序随机从对照条件(标准诊疗转诊门诊)转换为干预条件(立即启动治疗)。
  • 2019年10月1日至2021年12月31日共纳入200例HCV RNA阳性者,平均年龄47.4岁,男性72.5%,60.5%在过去3个月注射过毒品,20.4%有肝硬化。
  • 主要结局为治疗完成,定义为入组后六个月内配发处方治疗的最后一个药包。

主要发现

  • 干预条件下98例中67例完成治疗(68.4%[95%CI 58.2-77.4]),对照条件下102例中36例完成治疗(35.3%[95%CI 26.1-45.4]),风险差33.1%(95%CI 20.0-46.2),风险比1.9(95%CI 1.4-2.6)。
  • 干预在治疗完成方面更优(aOR 4.8[95%CI 1.8-12.8];P=.002)。
  • 干预在启动治疗时间方面更优(aHR 4.0[95%CI 2.5-6.3];P<.001)。
  • 持续病毒学应答干预条件下98例中60例(61.2%[95%CI 50.8-70.9]),对照条件下102例中66例(64.7%[95%CI 54.6-73.9])。

临床怎么用

  • 作者认为,住院注射吸毒者的HCV机会性检测-治疗模式应考虑更广泛实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to evaluate the efficacy of opportunistic treatment of hepatitis C virus (HCV) infection among hospitalized people who inject drugs (PWID). METHODS: We performed a pragmatic, stepped wedge cluster randomized trial recruiting HCV RNA positive individuals admitted for inpatient care in departments of internal medicine, addiction medicine, and psychiatry at three hospitals in Oslo, Norway. Seven departments were sequentially randomized to change from control conditions (standard of care referral to outpatient care) to intervention conditions (immediate treatment initiation). The primary outcome was treatment completion, defined as dispensing the final package of the prescribed treatment within six months after enrolment. RESULTS: A total of 200 HCV RNA positive individuals were enrolled between 1 October 2019 and 31 December 2021 (mean age 47.4 years, 72.5% male, 60.5% injected past 3 months, 20.4% cirrhosis). Treatment completion was accomplished by 67 of 98 (68.4% [95% confidence interval {CI}: 58.2-77.4]) during intervention conditions and by 36 of 102 (35.3% [95% CI: 26.1-45.4]) during control conditions (risk difference 33.1% [95% CI: 20.0-46.2]; risk ratio 1.9 [95% CI: 1.4-2.6]). The intervention was superior in terms of treatment completion (adjusted odds ratio [aOR] 4.8 [95% CI: 1.8-12.8]; P = .002) and time to treatment initiation (adjusted hazard ratio [aHR] 4.0 [95% CI: 2.5-6.3]; P < .001). Sustained virologic response was documented in 60 of 98 (61.2% [95% CI: 50.8-70.9]) during intervention and in 66 of 102 (64.7% [95% CI: 54.6-73.9]) during control conditions. CONCLUSIONS: An opportunistic test-and-treat approach to HCV infection was superior to standard of care among hospitalized PWID. The model of care should be considered for broader implementation. Clinical Trials Registration. NCT04220645.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Midgard H, Malme KB, Pihl CM, et al. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clin Infect Dis. 2024. PMID: 37992203. doi:10.1093/cid/ciad711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。